Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2255777 | 1.00 | MEN1 (0.31) | MEN1KMT2ARORC | |
| SCHEMBL2254865 | 0.91 | PIK3CA (0.35) | MEN1KMT2A | |
| SCHEMBL2252291 | 0.91 | PIK3CA (0.35) | MEN1KMT2A | |
| SCHEMBL2255999 | 0.91 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL2255735 | 0.91 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL2251868 | 0.90 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL2254859 | 0.90 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL2249636 | 0.89 | SCN1A (0.33) | — | |
| SCHEMBL2252821 | 0.89 | SCN1A (0.33) | — | |
| SCHEMBL401323 | 0.88 | ATM (0.37) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989455-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2011-08-02 | — | — | US | claimed |
| EP-1962852-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2008-09-03 | — | — | EP | claimed |
| US-20070197497-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | claimed |
| WO-2007078839-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-07-12 | — | — | WO | claimed |
| EP-1962852-B1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2017-01-25 | — | — | EP | disclosed |
| US-7989455-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| EP-1962852-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20070197497-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007078839-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197497-A1 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | MEN1 4344/4885KMT2A 4396/4885RORC 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.